HK1009331A1 - Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders - Google Patents

Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders Download PDF

Info

Publication number
HK1009331A1
HK1009331A1 HK98110056A HK98110056A HK1009331A1 HK 1009331 A1 HK1009331 A1 HK 1009331A1 HK 98110056 A HK98110056 A HK 98110056A HK 98110056 A HK98110056 A HK 98110056A HK 1009331 A1 HK1009331 A1 HK 1009331A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
pyridineethanamine
pharmaceutically acceptable
treatment
compound
Prior art date
Application number
HK98110056A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1009331B (en
Inventor
Conrad Griffith Ronald
John Murray Robert
Balestra Michael
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of HK1009331B publication Critical patent/HK1009331B/en
Publication of HK1009331A1 publication Critical patent/HK1009331A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK98110056A 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders HK1009331A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9207339 1992-04-03
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB9208290 1992-04-15
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
HK1009331B HK1009331B (en) 1999-05-28
HK1009331A1 true HK1009331A1 (en) 1999-05-28

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110056A HK1009331A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders

Country Status (29)

Country Link
EP (1) EP0633879B1 (cs)
JP (2) JP3120810B2 (cs)
KR (1) KR100259567B1 (cs)
CN (1) CN1044367C (cs)
AT (1) ATE163925T1 (cs)
AU (2) AU3897693A (cs)
CA (1) CA2133427C (cs)
CZ (1) CZ288519B6 (cs)
DE (1) DE69317411T2 (cs)
DK (1) DK0633879T3 (cs)
DZ (1) DZ1677A1 (cs)
ES (1) ES2115055T3 (cs)
FI (1) FI105025B (cs)
HK (1) HK1009331A1 (cs)
HU (1) HU211529A9 (cs)
IL (1) IL105276A (cs)
MA (1) MA22866A1 (cs)
MX (1) MX9301935A (cs)
MY (1) MY110149A (cs)
NO (1) NO302170B1 (cs)
NZ (1) NZ251384A (cs)
PL (1) PL180014B1 (cs)
RU (1) RU2128650C1 (cs)
SG (1) SG47948A1 (cs)
SK (1) SK281258B6 (cs)
TW (1) TW282455B (cs)
UA (1) UA29437C2 (cs)
WO (1) WO1993020052A1 (cs)
ZA (1) ZA932415B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
ES2250170T3 (es) * 1999-07-28 2006-04-16 Ortho-Mcneil Pharmaceutical, Inc. Derivados de aminas y de amidas utilizados como ligando para el receptor y5 del neuropeptido y, util en el tratamiento de la obesidad y otros trantornos.
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
US8013165B2 (en) * 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545
EP2791352A1 (en) * 2011-12-14 2014-10-22 Astrazeneca AB Gabr-a2 diagnostic
RU2695372C2 (ru) * 2013-11-05 2019-07-23 Астразенека Аб Пролекарства антагониста NMDA
KR20230026449A (ko) * 2020-06-23 2023-02-24 바이오하벤 테라퓨틱스 리미티드 (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA889252B (en) * 1987-12-11 1990-08-29 Syntex Lab Neuroprotective compounds
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
CA2133427C (en) 2003-06-10
DK0633879T3 (da) 1998-09-28
MY110149A (en) 1998-02-28
FI105025B (fi) 2000-05-31
MA22866A1 (fr) 1993-12-31
WO1993020052A1 (en) 1993-10-14
NO943645D0 (no) 1994-09-30
CZ240994A3 (en) 1995-12-13
UA29437C2 (uk) 2000-11-15
AU7545696A (en) 1997-02-13
SK281258B6 (sk) 2001-01-18
DZ1677A1 (fr) 2002-02-17
CA2133427A1 (en) 1993-10-14
SK117794A3 (en) 1995-05-10
AU3897693A (en) 1993-11-08
JPH07505385A (ja) 1995-06-15
ES2115055T3 (es) 1998-06-16
RU94042465A (ru) 1996-07-20
ZA932415B (en) 1993-10-22
FI944546A0 (fi) 1994-09-30
CN1081669A (zh) 1994-02-09
DE69317411T2 (de) 1998-07-30
NO943645L (no) 1994-11-16
RU2128650C1 (ru) 1999-04-10
SG47948A1 (en) 1998-04-17
NZ251384A (en) 1996-10-28
CN1044367C (zh) 1999-07-28
JP2000319259A (ja) 2000-11-21
IL105276A (en) 1997-06-10
AU705419B2 (en) 1999-05-20
DE69317411D1 (de) 1998-04-16
IL105276A0 (en) 1993-08-18
KR100259567B1 (ko) 2000-07-01
EP0633879B1 (en) 1998-03-11
NO302170B1 (no) 1998-02-02
FI944546L (fi) 1994-09-30
TW282455B (cs) 1996-08-01
HU211529A9 (en) 1995-11-28
EP0633879A1 (en) 1995-01-18
CZ288519B6 (cs) 2001-07-11
JP3120810B2 (ja) 2000-12-25
PL180014B1 (pl) 2000-11-30
ATE163925T1 (de) 1998-03-15
MX9301935A (es) 1994-08-31

Similar Documents

Publication Publication Date Title
EP0633879B1 (en) Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
HK1009331B (en) Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders
EP0691957B1 (en) (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament
DE69431050T2 (de) PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN
US5455259A (en) Compounds for the treatment of neurodegenerative disorders
EP0691958B1 (en) (s)-alpha-phenyl-2-pyridineethanamine benzoate and its use as a medicament
CA2028645A1 (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
TW390875B (en) (S) -<alpha>-phenyl-2-pyridineethanamine (S)-malate useful in therary, its perparing process and pharmaceutical composition comprising the same
EP1596856A2 (de) Arzneimittel enthaltend substituierte 2-aryl-aminoessigs ure -verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure-verbindungen

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20130331